Table 3.
Summary of blood sample analysis
| Thailand | Zimbabwe | Tanzania | KwaZulu-Natal | Soweto | African Sites | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CBVCT | SVCT | CBVCT | SVCT | CBVCT | SVCT | CBVCT | SVCT | CBVCT | SVCT | CBVCT | SVCT | |
| Initial HIV status (rapid testing) | ||||||||||||
| Negative | 3,727 (98•4%) |
3,775 (98•5%) |
5,126 (86•5%) |
5,187 (87•1%) |
4,284 (91•5%) |
4,028 (92•4%) |
4,041 (68•3%) |
4,107 (69•3%) |
6,116 (87•4%) |
5,806 (83•8%) |
19,567 (83•2%) |
19,128 (82•5%) |
| Positive | 44 (1•2%) |
34 (0•9%) |
788 (13•3%) |
760 (12•8%) |
290 (6•2%) |
252 (5•8%) |
1,851 (31•3%) |
1,798 (30•3%) |
874 (12•5%) |
1,111 (16•0%) |
3,803 (16•2%) |
3,921 (16•9%) |
| Discordant | 16 (0•4%) |
23 (0•6%) |
9 (0•2%) |
10 (0•2%) |
110 (2•3%) |
77 (1•8%) |
21 (0•4%) |
25 (0•4%) |
8 (0•1%) |
14 (0•2%) |
148 (0•6%) |
126 (0•5%) |
| Final HIV status | ||||||||||||
| Uninfected | 3,743 (98•8%) |
3,797 (99•1%) |
5,146 (86•9%) |
5,202 (87•3%) |
4,400 (93•9%) |
4,105 (94•2%) |
4,063 (68•7%) |
4,134 (69•7%) |
6,134 (87•7%) |
5,828 (84•1%) |
19,743 (83•9%) |
19,269 (83•1%) |
| Infecteda | 44 (1•2%) |
35 (0•9%) |
777 (13•1%) |
755 (12•7%) |
284 (6•1%) |
252 (5•8%) |
1,850 (31•3%) |
1,795 (30•3%) |
712 (10•2%) |
941 (13•6%) |
3,623 (15•4%) |
3,743 (16•2%) |
| Unknownb | 0 (0•0%) |
0 (0•0%) |
0 (0•0%) |
0 (0•0%) |
0 (0•0%) |
0 (0•0%) |
0 (0•0%) |
1 (0•0%) |
152 (2•2%) |
162 (2•3%) |
152 (0•7%) |
163 (0•7%) |
| MAA status (among samples classified as HIV infected) | ||||||||||||
| MAA negative | 43 (97•7%) |
33 (94•3%) |
750 (96•5%) |
711 (94•2%) |
251 (88•4%) |
228 (90•5%) |
1,733 (93•7%) |
1,667 (92•8%) |
668 (93•8%) |
879 (93•4%) |
3,402 (93•9%) |
3,485 (93•1%) |
| MAA positive, acute, and early infections |
1 (2•3%) |
2 (5•7%) |
27 (3•5%) |
43 (5•7%) |
33 (11•6%) |
24 (9•5%) |
115 (6•2%) |
127 (7•1%) |
44 (6•2%) |
61 (6•5%) |
219 (6•0%) |
255 (6•8%) |
| Not evaluateda | 0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
1 (0.1%) |
0 (0.0%) |
0 (0.0%) |
2 (0.1%) |
1 (0.1%) |
0 (0.0%) |
1 (0.1%) |
2 (0•1%) |
3 (0•1%) |
| Results of ARV drug testing (among samples classified as MAA positive, acute infection or early infection) | ||||||||||||
| ARV drugs detected | 0 (0•0%) |
0 (0•0%) |
2 (7•4%) |
1 (2•3%) |
6 (18•2%) |
4 (16•7%) |
5 (4•3%) |
7 (5•5%) |
1 (2•3%) |
3 (4•9%) |
14 (6•4%) |
15 (5•9%) |
| No ARV drugs detected c | 1 (100•0%) |
2 (100•0%) |
25 (92•6%) |
42 (97•7%) |
27 (81•8%) |
20 (83•3%) |
110 (95•7%) |
120 (94•5%) |
43 (97•7%) |
58 (95•1%) |
205 (93•6%) |
240 (94•1%) |
a
Five of the 7,366 participants who were confirmed to be HIV-infected were excluded from the incidence analysis because of missing CD4 cell count data (not evaluated by the MAA).
b
Three-hundred fifteen participants who had at least one reactive HIV rapid test were excluded from the analysis because it was not possible to confirm their HIV status. This included 292 participants who were excluded because of sample contamination and 23 participants who were excluded for other reasons.12
c
This group includes samples from participants with acute and early HIV infection (those samples were not tested for the presence of ARV drugs) and samples that did not have enough plasma remaining for ARV testing.12